Global Pharmaceutical Company Honors Former CEO with Permanent Legacy at
Alma Mater
PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:
GSK) today announced the establishment of two fellowships totaling $500,000
in honor of former Chief Executive Officer Jean-Pierre Garnier, to support
students enrolled at Stanford Graduate School of Business. Dr. Garnier, who
received his Masters of Business Administration from the school in 1974,
retired from GSK on May 21, 2008.
Dr. Garnier served as the CEO of GSK since its creation in 2001,
steering it through a complex merger and driving the development of one of
the strongest new product pipelines in the industry. These funds will
provide an ongoing tribute to his success as the leader of the world's
second-largest research-based pharmaceutical company.
"Every successful company invests in the business to grow the bottom
line," said Sir Christopher Gent, GSK Chairman. "We believe that business
should also invest in something less tangible, less quantifiable, but of
equal importance-building its reputation with the society it serves. GSK is
pleased to honor Dr. Garnier's legacy by providing funds that will help
develop the business leaders of tomorrow."
"This generous gift honors an alumnus whose leadership throughout his
career has changed lives, changed organizations, and ultimately changed the
world," said Robert L. Joss, Dean of the Stanford Graduate School of
Business. "The fellowships being established in his honor ensure that
Jean-Pierre Garnier will continue to have an impact on shaping the next
generation of principled, innovative, and insightful business leaders."
Investing in the Best and Brightest
To remain competitive, Stanford Business School must attract and enroll
the best and the brightest students. The school's international reputation
as a leader in management education is built on the quality and diversity
of its students, whose broad range of experiences and backgrounds fosters a
collaborative culture. The GSK funding will provide a permanent legacy to
support deserving students enrolled in programs at the school in two ways:
-- A gift of $350,000 has been allocated to establish The JP and Danyele
Garnier Fellowship Fund in the Graduate School of Business. This fund
will provide a permanent legacy from which regular income will be used
to underwrite tuition and fees of deserving candidates pursuing an MBA.
-- A gift of $150,000 has been allocated to establish The JP and Danyele
Garnier Fellowship Fund in the Graduate School of Business Summer
Institute in Entrepreneurship Program. The fund will enable Stanford
Business School to support students in a unique four-week program that
provides non-business school graduate students with a background in
business management fundamentals in finance, marketing, and accounting,
through a highly-interactive experience that also helps develop
foundational business skills, such as developing a business plan,
public speaking, and leadership.
"Not only has JP Garnier's leadership had a significant impact on GSK,
it has also been felt by individuals around the world-from the
establishment of the GSK African Malaria Partnership and the quest to
eliminate lymphatic filariasis in the developing world, to countless
community partnerships," Sir Christopher said. "JP Garnier has led GSK in
its challenging and inspiring mission: to improve the quality of human life
by enabling people to do more, feel better, and live longer. It is our hope
that the recipients of these endowments will go on to do the same in their
chosen fields."
About GlaxoSmithKline
GlaxoSmithKline, one of the world's leading research-based
pharmaceutical and health care companies, is committed to improving the
quality of human life by enabling people to do more, feel better, and live
longer.
About Stanford Graduate School of Business
The Stanford Graduate School of Business, located in northern
California's Silicon Valley, enrolls approximately 740 students in the
two-year full-time MBA Program, 105 candidates in the PhD Program, 56
mid-career executives in the 10-month Stanford Sloan Master's Program, and
more than 2,000 participants in Executive Education programs designed to
enhance executives' professional capabilities. For more information visit:
http://www.gsb.stanford.edu.
SOURCE GlaxoSmithKline
back to top
